RxSight (RXST) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to -$0.24.
- RxSight's EPS (Weighted Average and Diluted) fell 5000.0% to -$0.24 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.88, marking a year-over-year decrease of 731.71%. This contributed to the annual value of -$0.71 for FY2024, which is 4990.1% up from last year.
- Latest data reveals that RxSight reported EPS (Weighted Average and Diluted) of -$0.24 as of Q3 2025, which was down 5000.0% from -$0.29 recorded in Q2 2025.
- In the past 5 years, RxSight's EPS (Weighted Average and Diluted) registered a high of $0.09 during Q4 2021, and its lowest value of -$3.53 during Q2 2021.
- In the last 5 years, RxSight's EPS (Weighted Average and Diluted) had a median value of -$0.32 in 2025 and averaged -$0.52.
- The largest annual percentage gain for RxSight's EPS (Weighted Average and Diluted) in the last 5 years was 8271.95% (2022), contrasted with its biggest fall of 71111.11% (2022).
- Over the past 5 years, RxSight's EPS (Weighted Average and Diluted) (Quarter) stood at $0.09 in 2021, then tumbled by 711.11% to -$0.55 in 2022, then skyrocketed by 54.55% to -$0.25 in 2023, then soared by 38.88% to -$0.15 in 2024, then crashed by 57.07% to -$0.24 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.24 for Q3 2025, versus -$0.29 for Q2 2025 and -$0.2 for Q1 2025.